Editas Medicine, Inc.

Editas Medicine, Inc. (NASDAQ: EDIT) is a pioneering gene editing company dedicated to developing transformative genomic medicines to treat serious diseases. The company's website is www.editasmedicine.com.

Editas has developed a proprietary gene editing platform based on CRISPR technology, utilizing both Cas9 and Cas12a enzymes. The company believes it is the only human gene editing company with a platform encompassing CRISPR/Cas9, CRISPR/Cas12a, engineered forms of both systems, and foundational intellectual property for both, enabling potential targeting of more than 95 percent of the human genome. The platform's core advantage lies in its flexibility—guide RNA molecules can be rapidly reprogrammed to target new disease sites, and the company's diverse enzyme variants expand the number of genomic sites that can be targeted compared to commonly used single-enzyme approaches.

The company's lead program, EDIT-401, is an experimental in vivo gene-editing medicine designed to treat hyperlipidemia by upregulating the LDL receptor to reduce LDL cholesterol levels. Preclinical studies in non-human primates demonstrated approximately 90 percent mean LDL-C reductions with favorable tolerability. Editas is on track to submit an investigational new drug application by mid-2026 with expectations of achieving early human proof-of-concept data by year-end 2026.

Beyond its lead cardiovascular program, Editas is developing in vivo gene-editing approaches for hemoglobinopathies including sickle cell disease and transfusion-dependent beta thalassemia, targeting hematopoietic stem cells. The company is also advancing a "plug and play" lipid nanoparticle delivery platform designed to enable targeted delivery to multiple cell types and tissues.

Editas pursues a business development strategy combining internal development with in-licensing of complementary technologies. The company has established significant partnerships, including a collaboration with Bristol Myers Squibb advancing engineered T-cell therapies and a non-exclusive license agreement with Immatics for gamma-delta T cell therapies. Additionally, Editas licensed Cas9 technology to Vertex Pharmaceuticals for ex vivo gene editing in sickle cell disease and beta thalassemia, generating upfront payments and future milestone and royalty revenue.